International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 1135-1141 www.ijprajournal.com ISSN: 2456-4494

The Biological Importance of Aspirin on Various Disease

Yash Shinde[1], Priti Shinde[1], Pranjal Shinde[1], Rani Shidore[1], Priya Daingade[2]
1.Department of Pharmaceuticals, Genba Sopanrao Moze College of Pharmacy, Wagholi, Pune.
2.Associate Professor, Genba Sopanrao Moze College of Pharmacy, Wagholi, Pune.

Date of Submission: 15-12-2024 Date of Acceptance: 25-12-2024

ABSTRACT
Objective: - This study explores the therapeutic applications of aspirin, a compound with a rich history rooted in its derivation from willow bark, in various diseases. Over time, aspirin has become a cornerstone in modern medicine due to its versatile mechanisms of action, primarily the inhibition of platelet aggregation and COX-2 pathways. These properties have enabled its widespread use in the management of cardiovascular diseases, cerebrovascular conditions, cancer prevention, and pre-eclampsia. Its multifaceted benefits highlight its indispensability in both acute and preventive medical strategies.
Result: - Aspirin's efficacy in significantly reducing the risks of thrombosis, heart attacks, and strokes by modulating platelet activity. It also shows potential in oncology, particularly in lowering the incidence and progression of gastrointestinal cancers, through COX-2 inhibition and other cellular mechanisms. Additionally, in pregnancy, aspirin aids in preventing pre-eclampsia by enhancing placental blood flow and minimizing hypertensive complications. However, its use is accompanied by risks, including gastrointestinal bleeding and hypersensitivity reactions, which necessitate careful patient evaluation and dose optimization.
Conclusion: - Aspirin remains a vital pharmaceutical agent, offering substantial benefits in the prevention and management of a wide array of conditions. Despite its remarkable contributions to modern medicine, its associated risks highlight the importance of judicious use. Continuous research into its mechanisms and newer applications promises to enhance its therapeutic profile while mitigating adverse effects, ensuring its sustained relevance as a critical tool in pharmacotherapy.

Keywords: - Aspirin, Disease, Acetylsalicylic acid, Cardiovascular Disease, Cancer treatment, Respiratory Disease, Pre-eclampsia in pregnancy, Cerebrovascular therapy, Treatment

I. INTRODUCTION

Acetylsalicylic acid, commonly known as aspirin, has long been utilized across various medical disciplines. Its primary source is the willow bark, which has been used for its therapeutic properties for centuries. Historical records trace the use of willow bark as far back as 500 BC, with Chinese healers employing it in the treatment of different illnesses. Hippocrates, the father of medicine (430-377 BC), is known to have recommended willow bark, either chewed or powdered, to alleviate pain and reduce fever. In 100 AD, Greek surgeon Dioscorides noted that willow leaves could help reduce inflammation. Galen, another ancient physician, also used these leaves as medical agents in the 2nd century AD. When Europeans settled in America in the 1700s, they observed that indigenous peoples used willow bark for various ailments. However, it wasn't until July 2, 1763, that the fever-reducing properties of the willow bark were formally documented by Edward Stone, a priest. In 1828, Johann Buchner, a professor at the University of Munich, isolated bitter-tasting, yellow, needle-like crystals from the willow bark, naming the substance "Salicin," derived from "Salix" (Latin for willow). Earlier, in 1826, Italian researchers Brugnatelli and Fontana had produced salicin but with lower purity. Henri Leroux, a French chemist, succeeded in obtaining 30 grams of salicin from 1.5 kg of willow bark in 1829. By 1838, Italian chemist Raffaele Piria split salicin into sugar and an aromatic component through hydrolysis and oxidation, resulting in the formation of salicylic acid, a non-needle-like, colorless and purer compound.

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 1135-1141 www.ijprajournal.com ISSN: 2456-4494

*STRUCTURE



A) ASPIRIN IN CARDIOVASCULAR DISEASES-

*INTRODUCTION

Cardiovascular and cerebrovascular diseases encompass a range of conditions affecting the heart and brain, often caused by factors such as hyperlipidemia, hypertension, atherosclerosis, and blood viscosity. These conditions represent significant threats to human health, especially among people aged 50 and above. They are prevalent, lead to high rates of disability, and have a substantial mortality rate. Even with advanced medical treatment, more than 50% of survivors of cerebrovascular accidents cannot independently care for themselves. The global death toll from cardiovascular and cerebrovascular diseases exceeds 15 million annually, making them the leading cause of death worldwide.

*MECHANISM OF ACTION: -



Works primarily by inhibiting platelet cyclooxygenase (COX), thus preventing thrombosis. By suppressing platelet adhesion, aggregation, and release, it helps repair damaged

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 1135-1141 www.ijprajournal.com ISSN: 2456-4494

blood vessels and reduces the risk of cardiovascular events. Aspirin inhibits the production of thromboxane A2 (TXA2) by blocking the activity of platelet COX, thereby increasing the balance between prostacyclin 2 (PGI2) and TXA2. PGI2 is an antithrombotic substance that dilates blood vessels and prevents platelet aggregation, while TXA2 causes vasoconstriction and platelet activation. This shift helps to reduce the risk of thrombosis. Furthermore, aspirin plays a role in inhibiting atherosclerosis. It enhances nitric oxide synthase expression in vascular endothelial cells, leading to vasodilation and reduced platelet aggregation. Aspirin also helps return inflammatory markers, such as serum C-reactive protein (CRP), to normal levels, which reduces the risk of infarctions. Additionally, aspirin reduces oxidative stress, further preventing the progression of atherosclerosis.

*SIDE EFFECTS

The side effects of aspirin vary based on the dose. Low doses are generally well tolerated, while higher doses may cause nausea, vomiting, abdominal pain, and gastrointestinal issues such as bleeding or ulcers. Patients may experience tarry stools, indicating possible gastrointestinal bleeding. Other potential side effects include bronchial asthma, skin rashes, urticaria, and liver or kidney damage.

*CLINICAL USES

Aspirin serves different purposes depending on the dosage. In low doses, it primarily inhibits platelet aggregation, helping to prevent cerebral thrombosis. Medium doses offer antipyretic and analgesic effects, making it useful for treating colds, fever, and mild pain. High doses have anti-inflammatory and anti-rheumatic properties, making aspirin the drug of choice for treating conditions like acute rheumatic fever and arthritis.

B) ASPIRIN IN CANCER INTRODUCTION

Since its synthesis in 1897, aspirin has been explored for various medical uses, including its potential role in cancer prevention and treatment. Evidence suggests that aspirin reduces both cancer incidence and mortality, particularly in colorectal, esophageal, and gastric cancers. Its effects on breast, prostate, and lung cancer are less pronounced. While gastrointestinal bleeding is a known risk, serious consequences are rare in the targeted age group.

*MECHANISM OF ACTION



Studies from randomized controlled trials (RCTs) and observational studies suggest that aspirin not only prevents cancer incidence but also inhibits cancer progression and metastasis. The

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 1135-1141 www.ijprajournal.com ISSN: 2456-4494

most widely accepted mechanism involves the inhibition of COX-2, though other mechanisms may also play a role. These include inhibition of NF-kB, induction of polyamine catabolism, modulation of the mTOR signaling pathway, and activation of AMP-activated protein kinase. Additionally, aspirin's anti-platelet action might reduce the direct interaction between platelets and cancer cells, thereby preventing metastasis. However, higher doses (over 100 mg/day) seem to activate additional mechanisms beyond COX-2 inhibition.

*SIDE EFFECTS

Aspirin's most serious side effect is an increased risk of bleeding, particularly gastrointestinal or intracranial bleeding. While the risk of hemorrhagic stroke is modest, the overall benefit in reducing cancer risk typically outweighs this harm. GI bleeding is a common complication, though major bleeding episodes are rare, occurring in fewer than 1% of patients.

C) ASPIRIN-EXACERBATED RESPIRATORY DISEASE(AERD)

*INTRODUCTION

AERD is an acquired condition characterized by chronic eosinophilic inflammation of the sinuses, with or without asthma. It is triggered by the ingestion of COX-1 inhibiting NSAIDs, such as aspirin. The pathogenesis of this disease remains unclear, though significant advances have been made in understanding its inflammatory mechanisms. As knowledge of the underlying pathophysiology expands, new treatments may be developed to manage the condition more effectively.

*MECHANISM OF ACTION



AERD is a type 2 inflammatory condition marked by dysregulated arachidonic acid metabolism. Key inflammatory players include mast cells, eosinophils, basophils, and T-helper 2 (TH2) cells. In AERD patients, there is an upregulation of 5-lipoxygenase (5LO) and cysteinyl leukotriene receptors, leading to excessive production of cysteinyl leukotrienes. COX-1 inhibition exacerbates inflammation by halting the production of prostaglandin E2 (PGE2), which normally prevents mast cell activation and eosinophilic responses. This leads to bronchoconstriction, rhinitis, and in severe cases, hypotension and gastrointestinal symptoms. Interestingly, selective COX-2 inhibitors do not trigger the same inflammatory response in AERD patients, which allows for a targeted treatment approach.

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 1135-1141 www.ijprajournal.com ISSN: 2456-4494

*TREATMENT OPTIONS

Management of AERD primarily involves avoiding COX-1 inhibiting NSAIDs or undergoing aspirin desensitization. For those who require aspirin for cardiovascular reasons, desensitization followed by continuous aspirin therapy is often the best option. COX-2 inhibitors, such as celecoxib, are often safe alternatives for AERD patients, as they do not provoke respiratory reactions.

D) ASPIRIN IN CEREBROVASCULAR DISEASES

*ACUTE THERAPY

Randomized trials of aspirin in acute ischemic stroke patients have shown that aspirin reduces the risk of recurrent strokes and death. Notably, it does so without increasing the risk of hemorrhagic stroke, making it a vital tool in acute cerebrovascular therapy. This effect has been observed in large trials involving more than 40,000 patients.

*MECHANISM OF ACTION



Aspirin's mechanism of action in cerebrovascular diseases, such as ischemic stroke, centers on its antiplatelet effects, which reduce blood clot formation risk. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets, blocking the synthesis of thromboxane A2 (TXA2), a compound that promotes platelet aggregation and vasoconstriction. This inhibition lowers TXA2 levels, reducing platelet aggregation and clot formation within blood vessels. Additionally, this shift enhances the effect of prostacyclin (PGI2), which acts as a vasodilator and further prevents clotting, creating a balance that favors blood vessel openness. This antiplatelet effect is particularly beneficial for individuals at high risk of ischemic stroke, as it supports continuous blood flow, preventing recurrent strokes or transient ischemic attacks (TIA). Thus, aspirin's targeted action on COX-1 plays a critical role in reducing stroke risk in cerebrovascular disease patients.

*SECONDARY AND PRIMARY PREVENTION

Aspirin has proven beneficial in the secondary prevention of cerebrovascular events, reducing the risk of nonfatal strokes and vascular events. However, aspirin's role in primary prevention of strokes is more contentious, with mixed results across studies. Although aspirin is effective in preventing certain cerebrovascular events in high-risk patients, it increases the risk of hemorrhagic stroke, particularly in those with untreated hypertension.

*ADVERSE EFFECTS

Aspirin's inhibition of prostaglandin synthesis can lead to GI toxicity, renal impairment, and increased bleeding risk. GI symptoms, ranging

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 1135-1141 www.ijprajournal.com ISSN: 2456-4494

from nausea to major bleeding, are common side effects. In particular, aspirin-related GI bleeding can be a serious complication, especially in high doses. However, lowdose aspirin still carries a risk of minor GI issues.

E) ASPIRIN IN PRE-ECLAMPSIA IN PREGNANCY

*INTRODUCTION

Pre-eclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to organs, usually the liver and kidneys. It can lead to serious maternal and fetal complications if untreated.

*MECHANISM OF ACTION



Low-dose aspirin (81 mg) is used to prevent pre-eclampsia by inhibiting COX-1 in platelets, reducing the production of thromboxane A2, a molecule that promotes vasoconstriction and platelet aggregation.

This helps improve placental blood flow and reduces the likelihood of developing high blood pressure and other complications associated with preeclampsia.

*CLINICAL USES

Prevention of Pre-eclampsia: Aspirin is used in high-risk pregnant women (e.g., those with a history of pre-eclampsia, hypertension, or diabetes) to reduce the risk of developing pre-eclampsia.

*SIDE EFFECTS

Gastrointestinal Issues: Aspirin can cause GI irritation, but low-dose aspirin is generally well tolerated during pregnancy.

Bleeding Risk: Although rare, it can slightly increase the risk of bleeding, especially during delivery.

Allergic Reactions: Rare but can occur, particularly in individuals with aspirin sensitivity.

II. CONCLUSION

This project reviews how aspirin, originally used for pain relief, has become important in modern medicine for various treatments. Beyond easing pain, aspirin is used to prevent blood clots, which helps lower the risk of heart attacks and strokes. It also shows promise in

reducing the risk of certain cancers, especially colon cancer, by blocking processes that help cancer cells grow. Aspirin is also useful in managing high blood pressure complications in pregnancy (like pre-eclampsia) and treating specific respiratory conditions. However, it can cause side effects, such as stomach bleeding, especially at higher doses. This review highlights aspirin's many uses and benefits, while also considering its risks, making it a valuable but complex medication in both treatment and prevention.

REFERENCE

[1]. Ugurlucan M, Caglar IM, Caglar FN, Ziyade S, Karatepe O, Yildiz Y, Zencirci E, Ugurlucan FG, Arslan AH, Korkmaz S, Filizcan U, Cicek S. Aspirin: from a historical perspective. Recent Pat Cardiovasc Drug Discov. 2012 Apr;7(1):71-6. doi: 10.2174/157489012799

[2]. Keyu Chen 2022 6th International Seminar on Education, Management and Social Sciences (ISEMSS 2022), 312318, 2022362377. PMID: 22257089.

[3]. Thorat, M. A., & Cuzick, J. (2013). Role of Aspirin in Cancer Prevention. Current Oncology Reports, 15(6), 533–540. doi:10.1007/s11912-0130351-3

[4]. RU Lee, DD Stevenson - Allergy, asthma & immunology …, 2011 - synapse.koreamed.org

[5]. KM Woessner - Current allergy and asthma reports, 2017 – Springer

[6]. Eric H. Awtry MD From the Cardiology Section, Evans Department of Medicine, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Mass. View all articles by this author

[7]. Joseph Loscalzo MD, PhD From the Cardiology Section, Evans Department of Medicine, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Mass.View all articles by this author

[8]. The Eclampsia Trial Collaborative Group. (2020). "Low-dose Aspirin for Preventing Pre-eclampsia: A Review of the Evidence." British Medical Journal, 370, m3486. [DOI: 10.1136/bmj.m3486]

[9]. Bansal, T., & Gupta, S. (2015). Pharmacological Overview of Aspirin in Medicine. Indian Journal of Pharmacology, 47(4), 389-394. This article provides an in-depth look at aspirin's mechanisms of action and side effects, particularly for cardiovascular health.

[10]. Chatterjee, M., & Chatterjee, S. (2019). Aspirin and Other NSAIDs in Cancer Prevention. Indian Journal of Clinical Biochemistry, 34(3), 267272. This paper discusses aspirin's role in reducing cancer risk, specifically in gastrointestinal cancers, relevant to Indian healthcare practices.

[11]. Singh, R. B., & Beegom, R. (2003). Preventive Cardiology in India. Indian Heart Journal, 55(3), 225-234. This article includes information on aspirin's role in cardiovascular disease prevention within the Indian population.

[12]. Misra, S. (2010). Pharmacology for Undergraduate Students (pp. 112115). Jaypee Brothers Medical Publishers, New Delhi. This textbook covers basic pharmacology, including aspirin's uses, side effects, and contraindications, essential for understanding its impact in various therapies.

[13]. Kapoor, M., & Raju, V. (2017). Aspirin Use in Indian Patients: Benefits and Risks. Journal of Clinical and Diagnostic Research, 11(5), 8-13. This journal article explores the specific risks and benefits of aspirin use among Indian patients with different health profiles.

[14]. Gupta, R., & Sharma, M. (2018). Textbook of Medicine (10th Edition, pp. 452-456). Elsevier India. This medical textbook discusses aspirin's pharmacokinetics, common applications in clinical settings, and therapeutic implications for cardiovascular diseases.

[15]. Saxena, N., & Tiwari, S. (2016). Aspirin in Oncology: Prospects and Challenges. Indian Journal of Medical Research, 144(4), 405-411. This article discusses current research on aspirin's potential to prevent and manage certain cancers, with a focus on colorectal cancer.